14 15 Patients with diabetes mellitus (DM) are at high risk of developing peripheral arterial 16 obstructive disease (PAOD) in lower extremities. Previous studies show low level 17 LASER therapy (LLLT) can increase angiogenesis in vivo and in vitro. Here we 18 performed hindlimb ischemia as PAOD model on diabetic mice to test the effects of 19 LLLT. Twenty C57Bl/6 mice were randomly divided into four groups. Control group 20 mice received femoral artery ligation/excision only. DM group mice were injected 21 with Streptozocin (STZ) to induce diabetes followed by femoral artery 22 ligation/excision. LLLT group mice received femoral artery ligation/excision and the 23 lower limbs received LASER treatment for five days (660nm, 10 min, 1.91 J/cm 2 ) 24 started from second day postoperatively. DM+LLLT group mice were received 25 femoral artery ligation/excision and LASER treatment after diabetes induced. Three 26 days after LASER treatment finished, limb blood flow was measured by Laser 27 Doppler perfusion imaging. Capillary density was assessed by immunofluorescence 28 staining. CD31, VEGF, HIF-1, phospho-ERK, iNOS and eNOS protein level was 29 examined by Western blot. Blood perfusion, capillary density, CD31, and VEGF 30 protein levels were significantly higher in those groups received LLLT compared to 31 control and DM group. Low level LASER significantly increased ERK 32 phosphorylation and HIF-1 expression. In addition, phospho-eNOS was increased 33 but iNOS protein level was decreased in mice received LASER treatment. In 34 summary, the ability of low level LASER to induce therapeutic angiogenesis in 35 diabetic mice suggested this approach deserves investigation as a novel approach to 36 treat PAOD patients. 37 38 Introduction 39 Lower limb ischemia is often found in patients with diabetes mellitus (DM), and 40 peripheral arterial obstructive disease (PAOD) is one of major health care problems. 41 The age-adjusted prevalence of PAOD is 12%, and the prevalence of PAOD can be 42 expected to increase because of the aging population[1]. The primary 43 pathophysiology of PAOD is arterial stenosis or occlusion leading impair perfusion in 44 lower extremities. Symptomatic PAOD may cause intermittent claudication, which 45 induces pain during movements in affected limb, especially ambulation. In advanced 46 stage of PAOD, critical limb ischemia cause pain at rest and ulcer formation. These 47 different stages of PAOD produce functional impairments and restricts patient's 48 activity of daily livings. 49 The treatments for critical PAOD, which target improving longer-term cardiovascular 50 outcomes, include risk modification, exercise, wound management, endovascular and 51 surgical interventions[2]. Exercise can increase maximum walking time, improve 52 walking ability, and gait patterns in non-surgical patients[3]. Antiplatelet and lipid 53 lowering therapy delay the rate of PAD progression and reduce the incidence of new 54 onset intermittent claudication[4, 5]. In patients with critical limb ischemia, 55 therapeutic interventions such as revascularization and surgery have to be considered. 56 Endovascular treatment using percutaneous transluminal angioplasty can lower 57 morbidity and mortality in patients with femoropopliteal artery stenosis [6]. The 58 aims of surgical interventions are preventing limb loss, improving ulcer healing, 59 activity of daily living, quality of life, and survival rate[6]. In addition, therapeutic 60 angiogenesis was investigated whether it can ameliorate pain and improve exercise 61 capacity in patients with critical PAOD [7].

